However, regardless of the identity of the LL-37-driven mechanisms in the DC production protocol of this study, these mechanisms were able to work together and significantly enhance the functionality of the produced DCs, and this enhanced functionality translated into the in vitro induction of autologous CD8+ T cells with a superior potential to act against tumor cells in vitro. The gene discussed is CD8A; the disease is neoplasm.